This article has been updated with information and quotes from Myriad Genetics' Q2 earnings call. 

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its second quarter revenues in fiscal 2017 grew 2 percent, beating Wall Street expectations.

For the three months ended Dec. 31, the firm reported total revenues of $196.5 million, compared to $193.3 million in Q2 2016, and beating the consensus Wall Street estimate of $189.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.